TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03467256
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given IV
Study: NCT03467256
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT03467256
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT03467256
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT01603173
Drug: Quetiapine Fumarate Tablets 25 mg
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet once a day
Study: NCT01603173
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet once a day
Study: NCT00270127
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03103646
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
Study: NCT03103646
Drug: Itraconazole (200 mg)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Capsules for oral use, 200 mg/day. In a fed state
Study: NCT03103646
Drug: Itraconazole (300 mg)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg Capsules for oral use, 300 mg/day. In a fasted state.
Study: NCT04003844
Drug: Immunoglobulin G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
Study: NCT00400855
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study drug
Study: NCT01930604
Drug: Botox (onabotulinumtoxinA)
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT01930604
Drug: NaCl (placebo)
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006695
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/m2 IV on Day -6
Study: NCT00006695
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 BID on Days -5 through -2
Study: NCT00006695
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 BID on Days -5 through -2
Study: NCT00006695
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m2 IV on Day -1
Study: NCT00889850
Drug: 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
Normalized name: esomeprazole 40 MG
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg esomeprazole, single dose administration under fasted and fed condition
Study: NCT00889850
Drug: INexium 40 mg MUPS tablets (AstraZeneca, France)
Normalized name: esomeprazole 40 MG [Nexium]
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg esomeprazole, oral single dose administration under fasted and fed condition
Study: NCT04475107
Drug: Pyronaridine-Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pyramax
Study: NCT04068948
Drug: Meperidine
Normalized name: Meperidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study: NCT04068948
Drug: Hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study: NCT04068948
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study: NCT01963767
Drug: NT-020
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives.
Study: NCT04451200
Drug: Busulfan Injection
Normalized name: busulfan Injection
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injections doses will be personalized by PK at days -7 and -4
Study: NCT04277624
Drug: fezolinetant - test formulation
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04277624
Drug: fezolinetant - reference formulation
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03110029
Drug: Efinaconazole 10% Topical Application Solution [JUBLIA]
Normalized name: Efinaconazole 10% Topical application Solution [JUBLIA]
DrugBank: Efinaconazole (DB09040)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical efinaconazole 10% solution (Jublia)
Study: NCT02904369
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02904369
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02904369
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00674453
Drug: Lasofoxifene
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral tablet, 0.25 mg, daily, 2 years
Study: NCT02160158
Drug: Fesoterodine ER (fasted)
Normalized name: fesoterodine Extended Release Oral Tablet
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial Fesoterodine ER 4 mg (single dose)
Study: NCT02160158
Drug: Fesoterodine SR3 (fasted)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR3 4 mg (single dose)
Study: NCT02160158
Drug: Fesoterodine SR3 (fed)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR3 4 mg (single dose) with high-fat meal
Study: NCT00532129
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
Study: NCT00532129
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
Study: NCT02160158
Drug: Fesoterodine ER (fed)
Normalized name: fesoterodine Extended Release Oral Tablet
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
Study: NCT02160158
Drug: Fesoterodine SR3 (sprinkle)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
Study: NCT02160158
Drug: Fesoterodine SR4 (fasted)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR4 4 mg (single dose)
Study: NCT02160158
Drug: Fesoterodine SR4 (fed)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
Study: NCT02160158
Drug: Fesoterodine SR4 (sprinkle)
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
Study: NCT02386462
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
Study: NCT02386462
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04051047
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
Study: NCT00335972
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
Study: NCT06473259
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 courses of docetaxel 75 mg/sqm iv
Study: NCT03620032
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
Study: NCT03620032
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT06473259
Drug: Apalutamide Oral Tablet
Normalized name: apalutamide Oral Tablet
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg /daily orally
Study: NCT06473259
Drug: Enzalutamide Oral Tablet
Normalized name: enzalutamide Oral Tablet
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg /daily orally
Study: NCT06473259
Drug: Abiraterone acetate tablets
Normalized name: Abiraterone Acetate Tablets
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg /daily orally
Study: NCT06473259
Drug: Darolutamide Oral Tablet
Normalized name: darolutamide Oral Tablet
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg/daily orally
Study: NCT06473259
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3,75 mg im/4 w
Study: NCT01741181
Drug: Vitamin D supplementation
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 marketed by oneNine57
Study: NCT02603679
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any brand of paclitaxel may be used, excluding nab-paclitaxel
Study: NCT02603679
Drug: Tamoxifen + Palbociclib
Normalized name: Palbociclib
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any brand of tamoxifen may be used
Study: NCT02603679
Drug: Aromatase Inhibitor + Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any brand of letrozole, anastrozole or exemestane may be used
Study: NCT02603679
Drug: Goserelin + Aromatase Inhibitor + Palbociclib
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any brand of letrozole, anastrozole or exemestane may be used
Study: NCT01741493
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT01396187
Drug: PF-05231023
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg IV twice a week for 4 weeks
Study: NCT01396187
Drug: PF-05231023
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg IV twice a week for 4 weeks
Study: NCT01396187
Drug: PF-05231023
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IV twice a week for 4 weeks
Study: NCT01396187
Drug: PF-05231023
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV twice a week for 4 weeks
Study: NCT01504295
Drug: Metadoxine
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improve Liver Function and Reduce ALcohol Use
Study: NCT02469454
Drug: early insertion
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
Study: NCT01674504
Drug: Montelukast sodium chewable tablets 4 mg and 5 mg
Normalized name: montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study: NCT00756275
Drug: Nicotine Replacement Treatment (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
Study: NCT00756275
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
Study: NCT01721382
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00310531
Drug: Menostar (Estradiol, BAY86-5435)
Normalized name: Menostar
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
Study: NCT00310531
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene tbl. (60 mg/day)
Study: NCT02484963
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00622479
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be administered at 400mg BID for a 28 day cycle.
Study: NCT04477811
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin k1 tablets
Study: NCT04477811
Drug: Vitamin k2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin k2 45 ug tablets twice daily
Study: NCT02802592
Drug: Epogen
Normalized name: Epogen
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study: NCT01547000
Drug: extended-release guanfacine (Intuniv)
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
Study: NCT02257242
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 I.V. on Day 1 of each cycle
Study: NCT02257242
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2 I.V. on Day 1 and 2 of each cycle
Study: NCT02257242
Drug: Vincristine sulfate liposome injection
Normalized name: Vincristine Sulfate Liposome Injection
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose per dose escalation protocol, I.V. on Day 2 of each cycle
Study: NCT00276406
Drug: Pyridostigmine
Normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Study: NCT00988156
Drug: Eslicarbazepine acetate (BIA 2-093)
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Study: NCT00988156
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Study: NCT01303952
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
Study: NCT03909412
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
Study: NCT03909412
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.
Study: NCT03909412
Drug: Granulocyte Colony-Stimulating Factor
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
Study: NCT02882854
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 1 mg of guanfacine to take orally.
Study: NCT00565396
Drug: Fosinopril and Losartan
Normalized name: fosinopril and diuretics
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Study: NCT01127633
Drug: Solanezumab
Normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
Study: NCT01248442
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
Study: NCT00374881
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine
Study: NCT00374881
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine low dose
Study: NCT00688467
Drug: Navarixin
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
Study: NCT03497273
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib administered orally once daily at the protocol-defined dose.
Study: NCT03765216
Drug: 2L Polyethylene Glycol (PEG)
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
Study: NCT03765216
Drug: 4L Polyethylene Glycol (PEG)
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
Study: NCT00690794
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
Study: NCT00690794
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
Study: NCT00358319
Drug: Karenitecin
Normalized name: Karenitecin
DrugBank: Cositecan (DB05806)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00358319
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no